20
Participants
Start Date
July 31, 2025
Primary Completion Date
May 31, 2026
Study Completion Date
May 31, 2026
Risk managment
Behavioral lifestyle changes including an exercise program, healthy eating recommendations, reviewing medical management for cardiometabolic risk conditions, deprescribing review for brain toxic meds, online cognitive training, as well as recommendations to improve sleep quality, or smoking cessation as needed
Dasatinib
dasatinib 100mg The intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial
Quercetin (dietary supplement)
e intervention will involve the participant taking dasatinib 100mg and quercetin 1250ng combined, intermittenly throughout the trial
Vortioxetine
Participants will be prescribed vortioxetine to take daily, in combination with online cognitive training
RECRUITING
Washington University School of Medicine, St Louis
Washington University School of Medicine
OTHER